NCT00038844View on ClinicalTrials.gov

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

NACompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

December 31, 2007

Study Completion Date

September 30, 2010

Conditions
LymphomaLeukemia
Interventions
DRUG

Campath-1 H (Alemtuzumab)

Starting Dose of 15 mg by vein daily, 3 days in a row.

DRUG

Fludarabine

30 mg/m2 by vein daily, 3 days in a row.

DRUG

Cyclophosphamide

1 gm/m2 by vein daily, 3 days in a row.

DRUG

Rituximab

375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00038844 - Safety and Efficacy of Campath in Nonmyeloablative Transplantation | Biotech Hunter | Biotech Hunter